• 1
    Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 51220.
  • 2
    Raimondo G, Brunetto MR, Smedile A, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 1007.
  • 3
    Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C – natural history and cofactors. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 748.
  • 4
    Alberti A, Clumeck NECC Jury et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 61524.
  • 5
    Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 72331.
  • 6
    Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 212733. Review.
  • 7
    Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis c patients receiving peginterferon Alpha-2b plus ribavirin. Aliment Pharmacol Ther 2008. Epub ahead of print. DOI: DOI: 10.1111/j.1365-2036.2008.03823.
  • 8
    Overbeck K, Genné D, Golay A, Negro F. Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008; 49: 2958. Epub 22 May 2008.
  • 9
    Romero-Gomez M, Diago RJ, Andrade J, et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naëve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): Final results of a randomized and double-blinded trial. 54 Annual Meeting AASLD, San Francisco, 2008.
  • 10
    Manns MP, McHutchison JG, Gordon SC., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 11
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 12
    Kraus MR, Schäfer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11: 176974.
  • 13
    Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26: 65562.
  • 14
    Sulkowski M, Lawitz E, Shiffman ML, et al. Final results of the IDEAL phase IIIb study. Annual Meeting of the European Association for the Study of the Liver, Milan, Italy, 2008.
  • 15
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 80616.
  • 16
    Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 237.
  • 17
    Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005; 10: 3323.
  • 18
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 19
    Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 120711.
  • 20
    Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 418.
  • 21
    Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 9427.
  • 22
    Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 7938. Epub 2 April 2005.
  • 23
    Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 5316. Epub 13 December 2007.